ArticleJAAD international2026
Supporting evidence and recommendations for the management of patients with systemic-eligible atopic dermatitis: A Canadian consensus document.
Article in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis is a chronic, relapsing, and remitting inflammatory skin disease. Multiple systemic therapeutic options are available to treat atopic dermatitis. Objective: To provide evidence-based recommendations on the use of systemic therapies for atopic dermatitis in Canada that consider the nuances of the Canadian healthcare system and provide guidance for populations of clinical interest. Methods: A panel of 14 experts, including 11 dermatologists from Canada and 3 from the United States, reviewed available literature on systemic therapies for atopic dermatitis. The published evidence, along with clinical expertise and opinion, was used to draft a concise set of statements to guide healthcare providers in Canada on systemic treatment of atopic dermatitis. Results: During 3 rounds of virtual meetings with all 14 experts voting in all meetings, a total of 29 statements reached the 75% agreement required for consensus. Limitations: The consensus statements are based on expert opinions and consensus in the absence of evidence-based clinical research for patient outcomes. The statements represent considerations for patient management and not specific guidelines for patient treatment. Conclusion: The recommendations and statements provided serve to guide Canadian healthcare providers on the practical aspects of managing systemic-eligible patients with atopic dermatitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.